{
    "clinical_study": {
        "@rank": "139486", 
        "arm_group": [
            {
                "arm_group_label": "Lotemax gel + Restasis", 
                "arm_group_type": "Experimental", 
                "description": "Loteprednol etabonate ophthalmic gel 0.5% and cyclosporine ophthalmic emulsion 0.05% administered one drop of each medication into each eye, two times a day (BID) for 12-weeks."
            }, 
            {
                "arm_group_label": "Lotemax Gel", 
                "arm_group_type": "Experimental", 
                "description": "Loteprednol etabonate ophthalmic gel 0.5% administered one drop of medication into each eye, two times a day (BID) for 12-weeks."
            }, 
            {
                "arm_group_label": "Restasis", 
                "arm_group_type": "Experimental", 
                "description": "Cyclosporine ophthalmic emulsion 0.05% administered one drop of medication into each eye, two times a day (BID) for 12-weeks."
            }
        ], 
        "brief_summary": {
            "textblock": "This study is being conducted to investigate the safety, comfort, and tolerability of 3\n      treatments: Lotemax\u00ae gel 0.5% administered twice daily (BID)with or without Restasis 0.05%\n      administered BID, and Restasis 0.05% treatment alone for 12 weeks and at a follow-up safety\n      visit 1 week post-treatment. This study will also investigate the relative efficacy of\n      Lotemax gel 0.5% administered BID with or without Restasis 0.05% treatment administered BID\n      and of Restasis 0.05% treatment alone for the reduction of clinical signs or symptoms of\n      keratoconjunctivitis sicca (DED) over the first 4 weeks of a 12-week Treatment Period and at\n      the end of a 12-week Treatment Period."
        }, 
        "brief_title": "Lotemax\u00ae Gel 0.5% and Restasis 0.05% in Subjects With Mild or Moderate Keratoconjunctivitis Sicca", 
        "completion_date": {
            "#text": "February 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Keratoconjunctivitis Sicca", 
        "condition_browse": {
            "mesh_term": [
                "Keratoconjunctivitis Sicca", 
                "Dry Eye Syndromes", 
                "Keratoconjunctivitis"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Have been diagnosed with or treated for keratoconjunctivitis sicca (dry eye\n             disease[DED]) within 6 months prior to Visit 1.\n\n          -  Have a baseline (Visit 2) Intraocular pressure (IOP) measurement of \u2265 5 mmHg and \u2264 22\n             mmHg in each eye, with or without anti-glaucoma therapy.\n\n          -  Have mild to moderate DED in one eye or both eyes at Visit 1 and Visit 2.\n\n        Exclusion Criteria:\n\n          -  Have a known hypersensitivity to corticosteroids, cyclosporine, fluorescein,\n             lissamine green, topical anesthetic, or any component of either of the study drugs.\n\n          -  Have severe DED.\n\n          -  Have corneal erosive disease or other conditions suggestive of extensive damage of\n             the cornea.\n\n          -  Have a history of elevated IOP, a history of glaucoma, or IOP > 22 mm Hg in either\n             eye at the screening visit (Visit 1).\n\n          -  Have had penetrating intraocular surgery in the past 12 months or require penetrating\n             intraocular surgery during the study.\n\n          -  Have had eyelid surgery within the 6 months prior to Visit 1 or have DED secondary to\n             surgery.\n\n          -  Have visible evidence of anterior lid Demodex spp. infection or infestation\n\n          -  Have had corneal refractive surgery or corneal transplantation.\n\n          -  Have congenitally absent lacrimal or meibomian glands or have any obstructive disease\n             of the lacrimal glands, sarcoidosis, or any other lacrimal gland deficiency.\n\n          -  Have a diagnosis of on-going ocular infection, active anterior blepharitis, moderate\n             to severe pinguecula, Stevens-Johnson syndrome, ocular cicatricial pemphigoid,\n             significant conjunctival scarring, ocular chemical burn, or ocular neurotrophic\n             keratitis.\n\n          -  Have any serious systemic disease or uncontrolled medical condition that in the\n             judgment of the investigator could confound study assessments or limit compliance.\n\n          -  Have a history of ocular herpetic keratitis or have had active blepharitis in the 4\n             weeks prior to the first dose.\n\n          -  Have had ocular surgery (including laser) within 6 months prior to the first\n             Treatment Period, or plan or require ocular surgery during the study.\n             Neodymiumdoped:yttrium aluminum garnet (Nd:YAG) laser posterior capsulotomy is\n             allowed."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "40 Years"
        }, 
        "enrollment": {
            "#text": "100", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 21, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01817582", 
            "org_study_id": "813"
        }, 
        "intervention": [
            {
                "arm_group_label": "Lotemax gel + Restasis", 
                "intervention_name": "Lotemax Gel + Restasis", 
                "intervention_type": "Drug", 
                "other_name": [
                    "loteprednol etabonate gel 0.5%", 
                    "cyclosporine ophthalmic emulsion 0.05%"
                ]
            }, 
            {
                "arm_group_label": "Lotemax Gel", 
                "intervention_name": "Lotemax Gel", 
                "intervention_type": "Drug", 
                "other_name": "loteprednol etabonate 0.5%"
            }, 
            {
                "arm_group_label": "Restasis", 
                "intervention_name": "Restasis", 
                "intervention_type": "Drug", 
                "other_name": "cyclosporine ophthalmic emulsion 0.05%"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Cyclosporins", 
                "Cyclosporine", 
                "Loteprednol etabonate"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": "Dry Eye Disease", 
        "lastchanged_date": "November 22, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Irvine", 
                    "country": "United States", 
                    "state": "California", 
                    "zip": "92618"
                }, 
                "name": "Bausch & Lomb Incorporated"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "3", 
        "official_title": "A Randomized, Multi-Center, Parallel-Group, Safety and Efficacy Study of Lotemax\u00ae Gel 0.5% and Restasis 0.05% for 12 Weeks in Subjects With Mild or Moderate Keratoconjunctivitis Sicca (Dry Eye Disease; DED)", 
        "overall_official": {
            "affiliation": "Bausch & Lomb Incorporated", 
            "last_name": "Jon I Williams, PhD", 
            "role": "Study Director"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "December 2013", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "Corneal fluorescein staining", 
                "safety_issue": "No", 
                "time_frame": "Mean change from baseline to Visit 4(day 28)"
            }, 
            {
                "description": "Ocular Surface Disease Index (OSDI) Questionnaire to measure severity of dry eye. Total score through Visit 4.", 
                "measure": "Ocular Surface Disease Index", 
                "safety_issue": "No", 
                "time_frame": "Visit 4(day 28)"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01817582"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Participants will rate the severity of dry eye symptoms at on a 5-point grading scale for each of 8 symptoms and will then select their most bothersome symptom.", 
                "measure": "Worst Symptom Selection and Scoring", 
                "safety_issue": "No", 
                "time_frame": "Visit 2 (Day 0) - Visit 5 (Day 84)"
            }, 
            {
                "description": "Subject self-assessment questionnaire of ocular comfort after drug instillation. Graded on a 4 point scale where 0=comfortable and 3=severly uncomfortable", 
                "measure": "Ocular Comfort", 
                "safety_issue": "No", 
                "time_frame": "Visit 2 (Day 0) -  Visit 5 (Day 84)"
            }, 
            {
                "description": "50nL tear sample collected from each eye. Tear osmolarity for each sample will be read with the TearLab instrument in milliosmoles. Average values will be calculated.", 
                "measure": "Tear Osmolarity", 
                "safety_issue": "No", 
                "time_frame": "Visit 2 (day 0) - Visit 5 (day 84)"
            }, 
            {
                "description": "A measure of eye dryness; the cornea and conjunctiva are stained with fluorescein and tear film breakup time is determined.", 
                "measure": "Tear film break-up time (TFBUT)", 
                "safety_issue": "No", 
                "time_frame": "Visit 2 (day 0)  - Visit 5 ( day 84)"
            }, 
            {
                "description": "Corneal total fluorescein stain scoring for punctate keratopathy", 
                "measure": "Fluorescein Staining", 
                "safety_issue": "No", 
                "time_frame": "Visit 2 (day 0) - Visit 5 (day 84)"
            }, 
            {
                "description": "LG stain is for monitoring eye dryness in conjunctival tissue.", 
                "measure": "Lissamine green (LG) stain", 
                "safety_issue": "No", 
                "time_frame": "Visit 2 (day 0) - Visit 5 (day 84)"
            }, 
            {
                "description": "Subjects and Investigators will grade the overall improvement for change from baseline(Visit 2) in dry eye signs and symptoms for each subject at Visit 5", 
                "measure": "Dry eye signs and symptoms", 
                "safety_issue": "No", 
                "time_frame": "Visit 2 (day 0) - Visit 5 (day 84)"
            }, 
            {
                "description": "Degree of eye redness on a 4-point grading scale. Where 0=none and 3=severe", 
                "measure": "Eye Redness", 
                "safety_issue": "No", 
                "time_frame": "Visit 2 (day 0) - Visit 5 (day 84)"
            }, 
            {
                "description": "The Schirmer's test is a measure of the tonic secretion of the aqueous component of tears. The Schirmer's test will be conducted for both eyes.", 
                "measure": "Anesthetized Schirmer's Test", 
                "safety_issue": "No", 
                "time_frame": "Visit 1 (day -14) and Visit 6 (day 84)"
            }, 
            {
                "description": "Subjects and Investigators will grade the overall global improvement for change from baseline in dry eye signs and symptoms.", 
                "measure": "Global Improvement in Dry Eye", 
                "safety_issue": "No", 
                "time_frame": "Visit 2 (day 0) and Visit 5 (day 84)"
            }
        ], 
        "source": "Bausch & Lomb Incorporated", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Bausch & Lomb Incorporated", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "May 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "November 2013"
    }
}